Lemtrada Toxicity May Cause Arterial Dissection Leading To Strokes

Lemtrada Stroke Lawsuit News

Destruction of the smooth inside lining of the arteries is Lemtrada's primary drawback

Wednesday, January 13, 2021 - The immediate toxicity of Lemtrada causes arterial dissection, tears in the linings of arteries in the head and neck, and irritation and scarring of the inside arterial walls leading to the lungs, brain, and heart. Arterial dissection leading to the brain can cause blood clots that travel to the brain and cause a stroke. "An arterial dissection is a tear in the lining of an artery. When a tear occurs in a major artery in the head and neck - the carotid or vertebral arteries - that transmit blood to the brain, this is called a cerebral arterial dissection," according to

Lemtrada may cause microscopic irritation and bleeding that destroys the smooth lining of the interior of the arteries that is essential for blood to flow smoothly. When blood sticks to the inside of the arterial walls it clots and these clots can break free and travel to the smaller veins where they get stuck and prevent or decrease blood flow. Sanofi Genzyme, the maker of Lemtrada, has been accused by RRMS patients that have tried the drug and experienced arterial dissection or stroke, of failing to warn them of the potentially life-threatening risks of Lemtrada for more than four years after the drug first became available. If you fall into that category you should seek the guidance of a Lemtrada stroke heart attack lawyer to see if you qualify to file a Lemtrada stroke lawsuit against Sanofi. If you and your family have been injured by stroke or arterial dissection from Lemtrada you may seek compensation for lost wages, medical expenses, and pain and suffering. Lemtrada stroke and arterial dissection may cause instant death or permanent disability. Patients were given Lemtrada for four years without being told of the risk for serious life-threatening injury.

Lemtrada has been reported to be effective in slowing the progression of relapse-remitting multiple sclerosis, however, it also can cause strokes and heart attacks. Lemtrada is allowed by the government as a last resort, only after at least two other disease-modifying therapies (DMT) have been tried and failed. According to the MS Society, "Disease-modifying therapies (DMTs) aren't a cure for MS, but they can reduce how many relapses someone has and how serious they are. They can also slow down the damage caused by relapsing multiple sclerosis that builds up over time. There are over a dozen DMTs for MS available on the NHS," the Benioff Children's Hospital of San Francisco reports.

Lemtrada toxicity is so severe that physicians and their patients are required to fill out and sign a Lemtrada Risk Profile questionnaire and submit such to the FDA. Only then and in the presence of emergency medical equipment and personnel, usually in a hospital, can Lemtrada be administered. Lemtrada is given via an IV infusion drip once per day for five consecutive days and repeated one year later.

More Recent Lemtrada Stroke Lawsuit News:

No-Cost, No-Obligation Lemtrada Lawsuit Case Review If You or a Loved One Suffered from Lemtrada Stroke Complications

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.